Ruxolitinib phosphate

Ruxolitinib phosphate is a phosphate salt obtained by reaction ruxolitinib with one equivalent of phosphoric acid. Used for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Among its listed roles, it functions as a antineoplastic agent and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It includes a ruxolitinib. It is grouped under the following drug class(es): Antineoplastic agents and JAK inhibitors. Its therapeutic use is listed as dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include ruxolitinib monophosphate and ruxolitinib (as phosphate). Its PubChem CID is 25127112.

CAS No 1092939-17-7
Molecular Formula C17H21N6O4P
Molecular Weight 404.4 g/mol
Synonyms (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid

Frequently Asked Questions